Table 2.

Phase III placebo-controlled trials assessing maintenance strategies with single-agent poly (ADP-ribose) polymerase inhibitors (PARPi) after response to platinum-based chemotherapy. Additionally, the three trials in platinum-sensitive settings included patients with ≥2 lines of platinum therapy.

Trial/PARPi	Histology	BRCA mutation	HRD, excluding BRCA (assay)	Residual disease	CA125 level
Front-Line – Switch Maintenance
SOLO1 Olaparib	HGS 96% HGE 2% Mixed 2%	Germline 99% Somatic 1%	N/A	N/A	No rising
PRIMA Niraparib	HGS 95% HGE 3% Mixed 2%	Germline or somatic 30%	HRD 20% (Myriad Mychoice cut-off: ≥42%)	≤2 cm	Normal or 90% ↓ with chemotherapy
Front-Line – Continuation Maintenance in Three-Arm Design
VELIA Veliparib	HGS 100%	Germline 19% Somatic 7%	HRD 29% (Myriad Mychoice cut-off: ≥33%)	N/A	__
Platinum-Sensitive Recurrence – Switch Maintenance (PARPi-Naïve)
SOLO2 Olaparib	HGS 91% HGE 6% Mixed 3%	Germline 97% Somatic 0%	N/A	N/A	No rising
NOVA Niraparib	Predominantly HGS*	Germline 37% Somatic 8%	HRD 29% (Myriad Mychoice cut-off: ≥42%)	≤2 cm	Normal or 90% ↓ with chemotherapy
ARIEL3 Rucaparib	HGS 95% HGE 4% Mixed 1%	Germline or somatic 35%	LOH high 28% (Foundation medicine T5 cut-off: ≥16%)	N/A	Normal

*Non-HGS with gBRCAm were also eligible. Number of patients with other histologies has not been reported.

HGE, high-grade endometrioid; HGS, high-grade serous; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; mixed, HGS and HGE; N/A, not applicable; PARPi, poly (ADP-ribose) polymerase inhibitor.